Loading clinical trials...
Loading clinical trials...
A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Age
0 - 17 years
Sex
ALL
Healthy Volunteers
No
Children's Hospital Los Angeles
Los Angeles, California, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Hôpital Robert-Debré
Paris, France
Hospital San Juan De Dios
Barcelona, Spain
UCL Great Ormond Hospital
London, United Kingdom
Start Date
June 3, 2016
Primary Completion Date
September 17, 2020
Completion Date
November 4, 2020
Last Updated
October 8, 2021
13
ACTUAL participants
UCART19
BIOLOGICAL
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborators
NCT05054257
NCT06635330
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04690595